Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Mark Astrachan

Critical Insights From Ulta Beauty Analyst Ratings: What You Need To Know

Ratings for Ulta Beauty (NASDAQ:ULTA) were provided by 28 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.

Benzinga · Dec 9, 2024

Key Takeaways From Costco Wholesale Analyst Ratings

Analysts' ratings for Costco Wholesale (NASDAQ:COST) over the last quarter vary from bullish to bearish, as provided by 33 analysts.

Benzinga · Nov 29, 2024

Decoding 26 Analyst Evaluations For e.l.f. Beauty

In the latest quarter, 26 analysts provided ratings for e.l.f. Beauty (NYSE:ELF), showcasing a mix of bullish and bearish perspectives.

Benzinga · Nov 25, 2024

From analysis to the latest developments in health,
read the most diverse news in one place.

Stock Market Today: Stocks Swing Higher After Powell Speech

Fed Chair Powell poured cold water on potential rate cuts, but stocks jumped anyway.

Kiplinger · Dec 1, 2023

Pepsi Cozied Up To Celsius: What's Next For Coca-Cola/Monster? Access To Alcohol Via The Backdoor?

Activity in the energy drink market could pick up after a recent investment and distribution deal between PepsiCo Inc (NYSE: PEP) and Celsius Holdings Inc (NASDAQ: CELH).

Benzinga · Aug 8, 2022

Could PepsiCo Buy Out Celsius Holdings Or Monster Beverage? Why M&A In Energy Drinks Market Is Heating Up

As beverage companies compete to grow their non-carbonated drinks divisions, energy drink companies have often been subject to buyout rumors. A terminated distribution agreement between an energy drink company and a leading beverage company is leading to more merger and acquisition speculation in the industry.

Benzinga · Jun 24, 2022

Read Why Stifel Downgraded Reynolds Consumer Products

Stifel analyst Mark Astrachan downgraded Reynolds Consumer Products Inc (NASDAQ:REYN) to Hold from Buy with a reduced price target of $31, down from $33, implying an 8.7% upside. The analyst has reduced 2022 and 2023 EPS estimates below consensus, reflecting gross margin pressure from higher input costs. Astrachan expects volumes to worsen as the company…

Benzinga · Apr 13, 2022

Read news from The Economist, FT, and more,
with one subscription

Coverage From

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.